Robert S. Schwartz, Ph.D.

Robert S. Schwartz, Ph.D.

by | Jan 22, 2018

Bob has extensive experience litigating biotechnology and pharmaceutical patents, including those relating to antibodies, protein biochemistry, molecular biology, genomics and proteomics. Bob has a B.S. in Biology and a Ph.D. in Biochemistry. As a Principal...
Ha Kung Wong

Ha Kung Wong

by | Sep 29, 2016

Ha Kung has extensive experience litigating a wide variety of pharmaceutical cases, including those concerning biologics used to treat rheumatoid arthritis and autoimmune disorders.  He also has extensive experience consulting, conducting due diligence and licensing...
April Breyer Menon

April Breyer Menon

by | Jan 22, 2018

April has litigated various pharmaceutical and biotechnology cases, including concerning oncology treatments and DNA sequencing technology.  She has specialized in damages and commercial success arguments.  April has a B.S. in Genetics, Cell Biology and Development...
Katherine Adams

Katherine Adams

by | Feb 14, 2018

Katie has experience litigating a variety of pharmaceutical and biotechnology patents, including those relating to treatments for oncology and genetic disorders.  Katie received a B.S. degree in Neuroscience with high honors.
Christopher P. Borello

Christopher P. Borello

by | Jan 22, 2018

Chris has extensive experience litigating  and counseling clients on biotechnology and pharmaceutical patents including those relating to fusion proteins, immunomodulators, genetically modified animals, antibodies, chemical compounds, prodrugs and formulations.  Chris...

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha